Samsung Pharmaceutical Voluntarily Withdraws Domestic Phase 3 IND for GV1001 in Progressive Supranuclear Palsy... Plans to Resubmit After Supplementing Data
Samsung Pharmaceutical has voluntarily withdrawn its application for domestic Phase 3 investigational new drug (IND) approval for GV1001, a treatment for progressive supranuclear palsy (PSP). The company plans to comprehensively reflect the Ministry of Food and Drug Safety (MFDS)'s requests for addi

Samsung Pharmaceutical has voluntarily withdrawn its application for domestic Phase 3 investigational new drug (IND) approval for GV1001, a treatment for progressive supranuclear palsy (PSP). The company plans to comprehensively reflect the Ministry of Food and Drug Safety (MFDS)'s requests for additional data and resubmit the application as soon as possible.
[Voluntary Withdrawal on September 23 Following MFDS Request for Supplementary Data]
Samsung Pharmaceutical submitted the GV1001 Phase 3 IND application to the MFDS on July 1 and had been under review. However, during the MFDS's review process, the company was asked to supplement the submitted data. The company explained that it judged it appropriate to prepare materials comprehensively reflecting the relevant matters and then resubmit, and voluntarily withdrew the application on September 23.
[Phase 3 Trial in PSP-RS Patients... Aimed at Confirming Efficacy and Safety]
The clinical trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-design, prospective Phase 3 study to confirm therapeutic efficacy and safety by subcutaneously administering 0.56mg of GV1001 to patients with progressive supranuclear palsy Richardson syndrome (PSP-RS).
Samsung Pharmaceutical stated that it plans to supplement the relevant matters and resubmit the investigational new drug (IND) application as soon as possible.
[Statistical Approval Probability About 10%... Investment Caution Advised]
Through an investment caution disclosure, the company stated that the probability of a clinical trial drug ultimately receiving final approval as a medicine is statistically known to be about 10%, and that results during the item approval process may not meet expectations. It added that there is also a possibility of changing or abandoning its commercialization plans accordingly.
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.
![[Breaking] Cyberattack via Optimizely Exposes 178 Global Organizations... CNN, BBC, HSBC, and Ledger Also Affected](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F11%2F627874%2Ffc472b72a2596aa1%2Fvariants%2Fhero.webp&w=1920&q=75)


